Zai Lab (ZLAB) Common Equity (2016 - 2026)
Zai Lab (ZLAB) posted Common Equity of $662.0 million for Q1 2026, down 7.48% sequentially from $715.5 million in Q4 2025, and down 18.35% YoY from $810.8 million in Q1 2025.
Zai Lab (ZLAB) Common Equity (2016 - 2026) Analysis & Trends
Zai Lab has reported Common Equity for 11 years, with the latest figure at $662.0 million in Q1 2026.
- Quarterly Common Equity fell 18.35% year-over-year to $662.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $662.0 million (down 18.35% YoY) and the FY2025 annual result came in at $715.5 million, down 14.91% from the prior year.
- Common Equity retreated to $662.0 million in Q1 2026 per ZLAB's latest filing, from $715.5 million in the prior quarter.
- Over five years, Common Equity peaked at $1.3 billion in Q1 2022 and troughed at $662.0 million in Q1 2026.
- A 5-year average of $882.2 million and a median of $810.8 million in 2025 frame the typical range for Common Equity.
- The widest YoY moves for Common Equity: up 29.55% in 2022, down 30.36% in 2022.
- Over 5 years, Common Equity stood at $1.0 billion in 2022, then fell by 23.86% to $796.1 million in 2023, then gained by 5.62% to $840.9 million in 2024, then fell by 14.91% to $715.5 million in 2025, then slipped by 7.48% to $662.0 million in 2026.
- According to Business Quant data, Common Equity over the past three periods registered $662.0 million, $715.5 million, and $759.9 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Common Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 20.25 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 31.71 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 2.61 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 5.17 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 8.57 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 9.79 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 1.35 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 757.49 Mn |
| 10 | Zai Lab | 2.91 Bn | 2.20 Bn | 58.15 Mn | 607.04 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 607.04 Mn |
| Mar 31, 2026 | 661.98 Mn |
| Dec 31, 2025 | 715.50 Mn |
| Sep 30, 2025 | 759.95 Mn |
| Jun 30, 2025 | 791.74 Mn |
| Mar 31, 2025 | 810.75 Mn |
| Dec 31, 2024 | 840.90 Mn |
| Sep 30, 2024 | 667.67 Mn |
| Jun 30, 2024 | 704.18 Mn |
| Mar 31, 2024 | 762.17 Mn |
| Dec 31, 2023 | 796.12 Mn |
| Sep 30, 2023 | 880.98 Mn |
| Jun 30, 2023 | 932.31 Mn |
| Mar 31, 2023 | 1.00 Bn |
| Dec 31, 2022 | 1.05 Bn |
| Sep 30, 2022 | 1.11 Bn |
| Jun 30, 2022 | 1.21 Bn |
| Mar 31, 2022 | 1.31 Bn |
| Dec 31, 2021 | 1.38 Bn |
| Sep 30, 2021 | 1.59 Bn |